John Patrick Shannon Jr. - 30 Jan 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Executive Officer and Director, Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
30 Jan 2026
Net transactions value
-$2,506,117
Form type
4
Filing time
02 Feb 2026, 18:13:18 UTC
Previous filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shannon John Patrick Jr Chief Executive Officer and Director, Director C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 02 Feb 2026 0001553595

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +478,436 +17% $0.000000 3,276,083 30 Jan 2026 Direct F1
transaction XERS Common Stock Tax liability $869,466 -118,134 -3.6% $7.36 3,157,949 31 Jan 2026 Direct F2
transaction XERS Common Stock Tax liability $821,531 -111,621 -3.5% $7.36 3,046,328 31 Jan 2026 Direct F2
transaction XERS Common Stock Tax liability $815,120 -110,750 -3.6% $7.36 2,935,578 31 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Award $0 +639,639 $0.000000 639,639 30 Jan 2026 Common Stock 639,639 $7.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
F3 These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Executive Officer and Director